CASE REPORT: Resolution of Chemotherapy-Induced Lymphopenia in Waldenström’s Macroglobulinemia Following Compassionate Use of WF10

Abstract Bendamustin-Rituximab (BR) chemotherapy controls clonal B-cell expansion in Waldenström’s macroglobulinemia (WM) but may aggravate anemia and induce persistent lymphopenia. In the presented patient, the drug WF10 restored immune balance, reduced inflammation, and resolved anemia without interfering with chemotherapy (CT) effects on the tumor clone. No dedicated drug exists to counteract CT-induced lymphopenia in WM, despite its link to infections and secondary malignancies. This case highlights Immunokine as a post-CT option for resolving persistent lymphopenia, abating systemic inflammation, and restoring immune balance in WM patients. Tangible benefits included resolution of infection susceptibility, improved energy, and abatement of anemia – translating into better quality of life and resilience under CT. In the presented case, persistence of grade 1 lymphopenia suggests further WF10 treatment cycles may achieve full immune reconstitution.